Weekly Research Analysts’ Ratings Updates for Viking Therapeutics (VKTX)

Viking Therapeutics (NASDAQ: VKTX) has recently received a number of price target changes and ratings updates:

• 10/20/2026 – Viking Therapeutics had its price target lowered by Canaccord Genuity Group from $114.00 to $106.00. They now have a “buy” rating on the stock.
• 10/15/2026 – Viking Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/14/2026 – Viking Therapeutics is now covered by UBS Group. They set a “buy” rating and a $94.00 price target on the stock.
• 10/14/2026 – Viking Therapeutics was upgraded by UBS Group to “strong-buy”.
• 10/13/2026 – Viking Therapeutics was upgraded by Barclays to “strong-buy”.
• 10/7/2026 – Viking Therapeutics had its price target lowered by Truist Financial from $87.00 to $85.00. They now have a “buy” rating on the stock.
• 10/4/2026 – Viking Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/26/2026 – Viking Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/23/2026 – Viking Therapeutics had its price target raised by Truist Financial from $83.00 to $87.00. They now have a “buy” rating on the stock.
• 9/22/2026 – Viking Therapeutics was given a new $120.00 price target by Oppenheimer.
• 9/22/2026 – Viking Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 9/22/2026 – Viking Therapeutics had its “overweight” rating reaffirmed by Morgan Stanley.

Insider Transactions at Viking Therapeutics

In other news, CEO Brian Lian sold 148,517 shares of Viking Therapeutics stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $33.32, for a total transaction of $4,948,586.44. Following the completion of the transaction, the chief executive officer owned 2,572,441 shares of the company’s stock, valued at $85,713,734.12. The trade was a 5.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Greg Zante sold 21,217 shares of Viking Therapeutics stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $33.47, for a total value of $710,132.99. Following the transaction, the chief financial officer owned 212,204 shares of the company’s stock, valued at $7,102,467.88. This represents a 9.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 187,951 shares of company stock valued at $6,268,442 in the last quarter. 5.30% of the stock is currently owned by corporate insiders.

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company develops therapies for metabolic and endocrine disorders, with a focus on conditions involving obesity, nonalcoholic steatohepatitis (NASH), and other liver and lipid disorders.

Viking’s lead program is VK2735, an investigational dual GLP-1/GIP receptor agonist being developed in injectable and oral formulations for obesity and related metabolic conditions.